On Wednesday, the 6th of January, everyone’s favorite reverse-merger pink sheet Coronacrapper, Cytodyn (CYDY) will be holding the latest in a long series of amusing presentations which we lovingly refer to as “CONference Calls.” This one must be particularly important as the company issued not one, but two press releases about it.
Here is the agenda from the first press release, on the left, and the second, on the right:
Notice the difference? Some important language was added in the second press release. Was it really intended as a reminder to investors or was it a CYA warning to investors?
Lets examine just a few of these agenda items:
There is one particular country that is suspiciously absent from the list in item 1, and by extension item 5, the Philippines. Odd considering how much The NaDDir* and the touts all over the internet have been hyping it. Want to know why an EUA in the Philippines was simply never in the cards for Cytodyn, contrary to all of the misleading hype? Read all about it here.
How about item 3? The potential revenue for Cytodyn from loserlimab, should it ever be approved? Contrary to The NaDDir’s* claims of billions in revenue, the real revenue opportunity for the company is far more modest. Why? Because even loserlimab’s biggest boosters recognize that everything they claim it can do another drug, Selzentry, can already do (and likely do far better for pharmacological reasons). Selzentry is approved and has been on the market for so long there is already a generic version known as maraviroc.
And for all of that supposed CCR5 blocking magic, maraviroc sells a bit over $20mm a quarter in the USA. That’s it. Not 000s of millions, and certainly not billions.
The proper pricing comparison for loserlimab is not remdesivir, but maraviroc, which costs about $1600 per month (300mg pill. 2x a day) without insurance reimbursement.
A shorter course of treatment, say 300mg x2 per day for one or two weeks, for coronavirus, would be about $400-800.
Agenda item 6, is an update on the the “Long Hauler” study. Want an update? Here you go. The study is ALREADY behind schedule. It was supposed to start on December 21, 2020. That date was missed. Now it is scheduled to start on January 21, 2021. It was supposed to be a quick study, lasting only three months, now it is expected to run until late June, a full five months.
What about agenda item 8, Breakthrough Therapy Designation for loserlimab? This has already been explored at length in a post the 6th of October. It should set the record straight about Cytodyn’s REAL timeline with regards to applying for Breakthrough Therapy Designation with the FDA. Read it here. Hint: They already have applied, and they have already been rejected.
And then there is agenda item 9, GvHD Trial Status. That trial has been going nowhere fast for five years, and continues to go nowhere. Read all about it here.
Finally, item 11, the much talked about NASDAQ listing. Want to know why a NASDAQ listing is a virtual impossibility, based on currently available audited financials, for Cytodyn? Read all about that here and here.
Tomorrow should certainly be fun.
PS A great read on the Cytodyn CD12 trial is this Twitter thread here.
* Spelled Thusly For A Double Dose of That Sweet Sweet Stock Pimping